LBB Specialties (LBBS), a leader in specialty chemicals and aspect distribution in North America, introduced a strategic partnership with Clariant, a worldwide leader in specialty chemical manufacturing.
Through this collaboration, LBB Specialties will distribute Clariant’s pharmaceutical-grade high-functional excipients – together with their polyethylene glycols (PEGs) and VitiPure® portfolio – for ophthalmic applications within the North American Life Sciences market.
This partnership brings together LBB Specialties’ set up know-expertise in the ophthalmic marketplace with Clariant’s decades-long, time-lengthy experience in producing and supplying extraordinary PEGs, a critical component in many ophthalmic formulations.
Clariant’s pharmaceutical-grade PEGs, now a part of LBB Specialties’ innovative Life Sciences portfolio, make sure clients have access to excessive-overall performance ingredients designed for various ophthalmic products. From eye drops to gels, the addition of these PEGs strengthens LBB Specialties’ capability to fulfill the evolving needs of the pharmaceutical industry.
“At LBB Specialties, we’re dedicated to providing our customers with the very high-quality specialty pharmaceutical components,” said Seth Burns, Senior Vice President of Life Sciences at LBB Specialties. “Partnering with Clariant permits us to supply industry-main PEGs that offer consistency and overall performance for ophthalmic applications, offering our clients with the assurance they want at some point of the pharmaceutical lifecycle—from R&D to commercialization.”
“This partnership with LBB Specialties marks a substantial step in our commitment to serving the pharmaceutical industry,” said Vaios Barlas, Head of Health Care at Clariant. “Our attention on growing high-performance, pharmaceutical-grade excipients has always driven the boundaries of what’s possible in ophthalmic formulations. By leveraging LBB Specialties’ sturdy distribution network in North America, we are able to make certain that greater formulators and producers can get the access to our cutting-edge ingredients, ultimately driving innovation in ophthalmic applications.”
